Biopharmaceutical Manufacturing

Part I: Manufacturing of Recombinant Therapeutic Proteins.- Chapter 1. Single-Use Systems in Biopharmaceutical Manufacture: State of the Art and Recent Trends (Jossen et al.).- Chapter 2. Recent Developments in Bioprocess Monitoring Systems (Rahmatnejad et al.).- Chapter 3. Advances in Characterization of Industrial Bioreactors for Cell Culture Process (Fitschen et al.).- Chapter 4. Continuous Bioprocessing for Upstream Process - Perfusion Process (Chotteau et al.).- Chapter 5. Continuous Bioprocessing for Downstream (Gerstweiler).- Chapter 6. Towards Digital Twin for Biopharmaceutical Processes: Concept and Progress (Ding et al.).- Chapter 7. Integrated Process and Supply Chain Design and Optimization (Triantafyllou et al.).- Chapter 8. Production of Complex Proteins in Plants - From Farming to Manufacturing (Nausch et al.).- Chapter 9. Manufacturing of Recombinant Proteins Using Quality by Design (QbD) Methodology: Current Trend and Challenges (Shin and Landauer).- Chapter 10. Biopharma 4.0 for Biologics Manufacturing Under Pandemic Constraints (Schmidt et al.).- Chapter 11. Biopharma 4.0: Digital Technologies Driving Smart Manufacturing (Nargund et al.).- Part II: Manufacturing Aspects of Cell and Gene Therapy .- Chapter 12. Essential Aspects of Mesenchymal Stem Cell Manufacturing (Fleischhammer et al.).- Chapter 13. Towards a Continuous Production of Human Mesenchymal Stromal Cells in a Chemically Defined Medium: Opportunities and Challenges for a Robust and Scalable Expansion Process (Tasto and Salzig).- Chapter 14. Biomanufacturing Aspects of Gene Therapy (Warnock).- Chapter 15. Manufacturing and Quality of Advanced Therapeutics: Cellular Therapies, CAR-T and Gene Therapies (van den Bos et al.).

Prof. Dr.-Ing. Ralf Pörtner: Senior research associate and group leader at Hamburg University of Technology, Institute of Bioprocess and Biosystems Engineering and Honorary Professor at TH Mittelhessen University of Applied Sciences, Giessen. The main research interests of Prof. Pörtner are development and optimization of bioreactor techniques and process strategies, in particular for cell cultures and microbial reactions, including model-based control concepts, and tissue engineering. He has in total published about 150 peer-reviewed papers.